Alkylamides from Echinacea Are a New Class of Cannabinomimetics

  title={Alkylamides from Echinacea Are a New Class of Cannabinomimetics},
  author={Stefan Raduner and A. Majewska and Jian-zhong Chen and Xiang-Qun Sean Xie and Jacques Hamon and Bernard Faller and Karl‐Heinz Altmann and J{\"u}rg Gertsch},
  journal={Journal of Biological Chemistry},
  pages={14192 - 14206}
Alkylamides (alkamides) from Echinacea modulate tumor necrosis factor α mRNA expression in human monocytes/macrophages via the cannabinoid type 2 (CB2) receptor (Gertsch, J., Schoop, R., Kuenzle, U., and Suter, A. (2004) FEBS Lett. 577, 563–569). Here we show that the alkylamides dodeca-2E,4E,8Z,10Z-tetraenoic acid isobutylamide (A1) and dodeca-2E,4E-dienoic acid isobutylamide (A2) bind to the CB2 receptor more strongly than the endogenous cannabinoids. The Ki values of A1 and A2 (CB2 ∼60 nm… 

Figures and Tables from this paper

New Natural Noncannabinoid Ligands for Cannabinoid Type-2 (CB2) Receptors
N-alkyl amide secondary metabolites from plants are found to constitute a new class of cannabinomimetics, which specifically engage and activate the cannabinoid type-2 (CB2) receptors, which are believed to play an important role in distinct pathophysiological processes.
Beta-caryophyllene is a dietary cannabinoid
Peroral (E)-BCP at 5 mg/kg strongly reduces the carrageenan-induced inflammatory response in wild-type mice but not in mice lacking CB2 receptors, providing evidence that this natural product exerts cannabimimetic effects in vivo.
Falcarinol is a covalent cannabinoid CB1 receptor antagonist and induces pro-allergic effects in skin.
Synthesis and cannabinoid receptor activity of ketoalkenes from Echinacea pallida and nonnatural analogues.
No significant activity was observed at either receptor, indicating that the ketoalkenes from E. pallida are not responsible for immunomodulatory effects mediated via the cannabinergic system, however, newly synthesized non-natural analogues showed micro-molar potency at both cannabinoid receptors.
Echinacea-induced cytosolic Ca2+ elevation in HEK293
It is shown that unidentified compounds from Echinacea purpurea induce cytosolic Ca2- elevation in non-immune-related cells, which lack CB2 receptors and that the Ca2+ elevation is not influenced by alkamides.
Identification of CB1/CB2 ligands from Zanthoxylum bungeanum.
The objective of this screen was to identify novel antagonists of the CB1 receptor, which simultaneously displayed agonist activity against the CB2 receptor, since compounds matching this criterion could be potential candidates for the treatment of type-1 diabetes.


Molecular characterization of a peripheral receptor for cannabinoids
The cloning of a receptor for cannabinoids is reported that is not expressed in the brain but rather in macrophages in the marginal zone of spleen, which helps clarify the non-psychoactive effects of cannabinoids.
Presence and regulation of the endocannabinoid system in human dendritic cells.
It is demonstrated for the first time that the endogenous cannabinoid system is present in human dendritic cells and can be regulated by cell activation.
Bioavailability and Pharmacokinetics of Alkamides From the Roots of Echinacea angustifolia in Humans
A sensitive and specific method has been developed for the identification and quantification of these alkamides in human plasma using liquid chromatography electrospray ionization ion‐trap mass spectrometry and was applied to analyze plasma samples obtained from a randomized, open, single‐dose, crossover study.
The cannabinoid system and immune modulation
It appears the immunocannabinoid system is involved in regulating the brain‐immune axis and might be exploited in future therapies for chronic diseases and immune deficiency.
Agonist-Directed Trafficking of Response by Endocannabinoids Acting at CB2 Receptors
Endocannabinoid agonists distinctly bind to CB2 receptors and display different rank order of potencies and fractional receptor occupancies for regulation of intracellular effectors, providing direct evidence for agonist-directed trafficking of response by endocannabinoids acting atCB2 receptors.
Evidence for Cannabinoid Receptor-Dependent and -Independent Mechanisms of Action in Leukocytes
The demonstration that cannabinoid-induced inhibition of PMA/Io-stimulated interleukin-2 was not mediated via CB1 or CB2 is suggested, which suggests that immune modulation produced by cannabinoids involves multiple mechanisms, which might be both cannabinoid receptor-dependent and -independent.
The endocannabinoid system as a target for alkamides from Echinacea angustifolia roots.
Most of the alkamides showed good metabolic stability as indicated by the similarity between affinity to CB1 determined in the presence/absence of the protease inhibitor PMSF, and it is suggested that CB2 interactions may be the molecular mode of action of Echinacea alkamide as immunomodulators.
Cannabinoid receptor as a novel target for the treatment of prostate cancer.
The results suggest that WIN-55,212-2 or other non-habit-forming cannabinoid receptor agonists could be developed as novel therapeutic agents for the treatment of prostate cancer.